A landmark study involving 9,535 patients across 29 countries has validated tranexamic acid as an effective intervention for reducing major bleeding during surgery. The TRACTION trial, published in The New England Journal of Medicine, demonstrates a 30% reduction in bleeding complications compared to placebo, with benefits consistently observed across cardiac, orthopedic, and abdominal procedures.
The international scope of the research ensures findings are applicable across diverse healthcare settings and surgical practices worldwide. Notably, the antifibrinolytic drug showed no increase in thrombotic complications despite theoretical concerns about clotting risks. This pragmatic, large-scale evidence base positions tranexamic acid as a simple, low-cost intervention with potential to save thousands of lives globally and improve outcomes in routine surgical practice.
Read the full article on GMJ Newsroom.
Was this article helpful?
